Newron Pharmaceuticals S.p.A. Stock
Stocks
NWRN
IT0004147952
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Swiss Exchange
18:31:41 16/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 8.200 CHF | +0.12% |
|
+8.04% | -65.62% |
| Market Cap | 188M 211M 174M 158M 299M 20.06B 304M 2.09B 821M 10.47B 793M 776M 33.37B | P/E 2026 * |
-5.61x | P/E 2027 * | 14.9x |
|---|---|---|---|---|---|
| Enterprise Value | 202M 227M 187M 170M 322M 21.58B 327M 2.25B 883M 11.26B 853M 835M 35.9B | EV / Sales 2026 * |
24.3x | EV / Sales 2027 * | 3.56x |
| Free-Float |
87.16% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| NWRN | Delayed | |
Xetra
| NP5 | Delayed | |
|
Tradegate
| NP5 | Real-time | |
|
Boerse Muenchen
| NP5 | Real-time | |
|
Deutsche Boerse AG
| NP5 | Delayed | |
|
CBOE
| 0QOI | Real-time | |
|
Börse Stuttgart
| NP5 | Delayed |
Last Transcript: Newron Pharmaceuticals S.p.A.
| 1 day | +0.12% | ||
| 1 week | +8.04% | ||
| Current month | +1.86% | ||
| 1 month | -24.49% | ||
| 3 months | -29.19% | ||
| 6 months | -50.12% | ||
| Current year | -65.62% |
| 1 week | 7.4 |  | 8.63 |
| 1 month | 5.72 | | 11.56 |
| Current year | 5.72 | | 31.85 |
| 1 year | 5.72 | | 31.85 |
| 3 years | 4.09 | | 31.85 |
| 5 years | 1.01 | | 31.85 |
| 10 years | 0.9 | | 31.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 62 | 15/05/2012 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01/01/2012 |
Filippo Moriggia
COO | Chief Operating Officer | - | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Stefan Weber
BRD | Director/Board Member | 62 | 15/05/2012 |
Gillian Dines
BRD | Director/Board Member | - | 01/04/2023 |
Margarita Chavez
BRD | Director/Board Member | - | 17/04/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/12/26 A | Buy | Chief Executive Officer | 2,000 | 0.0096% | ||
| 8/11/26 A | Buy | Chief Technology Officer | 582 | 0.0028% | ||
| 8/10/26 A | Buy | Chief Technology Officer | 1,418 | 0.0068% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.12% | +8.04% | -38.90% | +57.69% | 211M | |
| -6.60% | -8.56% | +49.38% | +63.51% | 65B | |
| +0.03% | +5.56% | +9.10% | +69.05% | 51.2B | |
| -4.09% | -0.11% | +2.22% | +53.15% | 51.19B | |
| -1.53% | +2.70% | +30.48% | +34.12% | 43.93B | |
| -1.34% | +4.12% | +16.64% | +115.13% | 41.96B | |
| -5.97% | -6.22% | +228.95% | +454.22% | 38.14B | |
| +6.53% | +8.02% | +16.40% | +53.41% | 33.24B | |
| -0.90% | -10.49% | +37.09% | -3.70% | 25.2B | |
| -1.07% | +2.33% | +19.43% | +9.98% | 22.5B | |
| Average | -1.48% | +0.49% | +37.08% | +90.66% | 37.26B | |
| Weighted average by Cap. | -2.19% | -0.49% | +44.20% | +96.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.31M 9.35M 7.71M 7.01M 13.23M 888M 13.44M 92.63M 36.32M 463M 35.1M 34.35M 1.48B | 57.89M 65.13M 53.66M 48.82M 92.12M 6.18B 93.6M 645M 253M 3.23B 244M 239M 10.28B |
| Net income | -32.8M -36.9M -30.4M -27.66M -52.2M -3.5B -53.03M -365M -143M -1.83B -138M -136M -5.83B | 9.39M 10.57M 8.7M 7.92M 14.94M 1B 15.18M 105M 41.02M 523M 39.65M 38.81M 1.67B |
| Net Debt | 14.21M 15.99M 13.17M 11.98M 22.61M 1.52B 22.98M 158M 62.07M 792M 60M 58.72M 2.52B | 18.13M 20.4M 16.81M 15.29M 28.85M 1.94B 29.32M 202M 79.2M 1.01B 76.55M 74.92M 3.22B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/10/26 | CHF 8.200 | +0.12% | 79,760 |
| 15/10/26 | CHF 8.190 | +2.89% | 53,292 |
| 14/10/26 | CHF 7.960 | +7.57% | 68,090 |
| 13/10/26 | CHF 7.400 | -7.15% | 92,387 |
| 12/10/26 | CHF 7.970 | +5.01% | 104,563 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NWRN Stock
Select your edition
All financial news and data tailored to specific country editions
